SEATTLE — Lisa Hark, PhD, director of glaucoma research at Wills Eye Hospital in Philadelphia, discusses data she is presenting at the Association for Research in Vision and Ophthalmology meeting on the incidence of glaucoma found in underserved populations in Philadelphia, particularly among African Americans.
VIDEO: HARBOR study data shows need for monitoring AMD patients
SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Rahul B. Khurana, MD, discusses a study looking at the as-needed arm of the HARBOR study, which showed the need for physicians to regularly monitor their patients with neovascular AMD.
Anti-VEGF therapy did not maintain visual acuity gains in AMD patients at 5 years
SEATTLE — Patients with neovascular age-related macular degeneration who were treated with anti-VEGF therapy did not maintain visual gains at 5 years, according to the Comparison of Age-Related Macular Degeneration Treatment Trials results presented here. “Our primary goal of the CATT follow-up study was to assess the overall visual acuity and morphologic outcomes at 5 years of any anti-VEGF treatment,” Daniel F. Martin, MD, said at the Association for Research in Vision and Ophthalmology meeting.
Telemedicine improves detection, management of glaucoma
SEATTLE — Community-based telemedicine can improve detection and management of patients with high-risk glaucoma and other diseases, according to a poster presented here.The Wills Eye Glaucoma Research Center initiated a 5-year community-based telemedicine intervention to improve the detection and management of high-risk glaucoma patients in Philadelphia, Lisa A. Hark, MD, and colleagues said at the Association for Research in Vision and Ophthalmology meeting.
In Vivo Confocal Microscopic Analysis of Corneal Nerve Changes After ProKera SlimĀ® for Dry Eye
Status: Active, not recruiting,
Condition Summary: Dry Eye Disease
Anti-VEGF Tx for Wet AMD Shows Benefit 5 Years Later (CME/CE)
(MedPage Today) — Half of patients still had 20/40 vision or better